CD8A and neoplasm: Recently, growing evidence have proved the favoured clinical outcomes mainly depend on cytokine‐ and chemokines‐driven CD8 positive T cell infiltration and the reduction of other suppressive immune cells in tumour microenvironment, which is accepted as an effective biomarker to predict the clinical efficacy of ICB interventions, except for those with high tumour mutation burden (TMB) and other neoantigens.5, 6, 7